Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 4:40 pm Purchase |
2024-09-30 | 13G | TScan Therapeutics, Inc. TCRX |
BIOTECHNOLOGY VALUE FUND L P | 5,073,003 9.990% |
658,093 (+14.91%) |
Filing History |
| 2024-11-14 4:39 pm Sale |
2024-09-30 | 13G | Ovid Therapeutics Inc. OVID |
BIOTECHNOLOGY VALUE FUND L P | 3,853,818 5.400% |
-2,997,233 (-43.75%) |
Filing History |
| 2024-11-14 4:38 pm Purchase |
2024-09-30 | 13G | Verastem, Inc. VSTM |
BIOTECHNOLOGY VALUE FUND L P | 4,279,521 9.990% |
1,662,119 (+63.50%) |
Filing History |
| 2024-11-14 4:37 pm Purchase |
2024-09-30 | 13G | Molecular Templates, Inc. MTEM |
BIOTECHNOLOGY VALUE FUND L P | 672,767 9.990% |
135,341 (+25.18%) |
Filing History |
| 2024-11-14 4:37 pm Sale |
2024-09-30 | 13G | Mirum Pharmaceuticals, Inc. MIRM |
BIOTECHNOLOGY VALUE FUND L P | 3,075,907 6.400% |
-1,294,117 (-29.61%) |
Filing History |
| 2024-11-14 4:36 pm Purchase |
2024-09-30 | 13G | Annexon, Inc. ANNX |
BIOTECHNOLOGY VALUE FUND L P | 9,027,778 8.400% |
2,027,778 (+28.97%) |
Filing History |
| 2024-11-14 4:36 pm Purchase |
2024-09-30 | 13G | AC Immune S.A. ACIU |
BIOTECHNOLOGY VALUE FUND L P | 19,522,436 19.700% |
4,951,200 (+33.98%) |
Filing History |
| 2024-11-14 4:34 pm Purchase |
2024-09-30 | 13G | Tyra Biosciences, Inc. TYRA |
BIOTECHNOLOGY VALUE FUND L P | 4,661,194 8.800% |
1,921,599 (+70.14%) |
Filing History |
| 2024-11-14 4:33 pm Sale |
2024-09-30 | 13G | Viracta Therapeutics, Inc. VIRX |
BIOTECHNOLOGY VALUE FUND L P | 0 0.000% |
-3,833,785 (Position Closed) |
Filing History |
| 2024-11-14 4:32 pm Sale |
2024-09-30 | 13G | Kura Oncology, Inc. KURA |
BIOTECHNOLOGY VALUE FUND L P | 4,212,346 5.400% |
-3,160,882 (-42.87%) |
Filing History |
| 2024-11-14 4:32 pm Purchase |
2024-09-30 | 13G | Regulus Therapeutics Inc. RGLS |
BIOTECHNOLOGY VALUE FUND L P | 883,844 1.300% |
883,844 (New Position) |
Filing History |
| 2024-11-14 4:30 pm Sale |
2024-09-30 | 13G | Sutro Biopharma, Inc. STRO |
BIOTECHNOLOGY VALUE FUND L P | 0 0.000% |
-3,347,946 (Position Closed) |
Filing History |
| 2024-11-14 4:30 pm Sale |
2024-09-30 | 13G | 89bio, Inc. ETNB |
BIOTECHNOLOGY VALUE FUND L P | 6,811,631 6.400% |
-756,849 (-10.00%) |
Filing History |
| 2024-11-14 4:29 pm Sale |
2024-09-30 | 13G | AN2 Therapeutics, Inc. ANTX |
BIOTECHNOLOGY VALUE FUND L P | 0 0.000% |
-1,563,963 (Position Closed) |
Filing History |
| 2024-11-14 4:29 pm Purchase |
2024-09-30 | 13G | Unicycive Therapeutics, Inc. UNCY |
BIOTECHNOLOGY VALUE FUND L P | 1,047,123 9.990% |
700,101 (+201.74%) |
Filing History |
| 2024-11-14 4:28 pm Purchase |
2024-09-30 | 13G | Elevation Oncology, Inc. ELEV |
BIOTECHNOLOGY VALUE FUND L P | 6,230,845 9.990% |
1,779,960 (+39.99%) |
Filing History |
| 2024-11-14 4:27 pm Sale |
2024-09-30 | 13G | Protagonist Therapeutics, Inc. PTGX |
BIOTECHNOLOGY VALUE FUND L P | 2,970,427 4.900% |
-2,793,521 (-48.47%) |
Filing History |
| 2024-11-14 4:27 pm Purchase |
2024-09-30 | 13G | Zymeworks Inc. ZYME |
BIOTECHNOLOGY VALUE FUND L P | 4,607,935 6.500% |
4,607,935 (New Position) |
Filing History |
| 2024-11-14 4:26 pm Purchase |
2024-09-30 | 13G | CytomX Therapeutics, Inc. CTMX |
BIOTECHNOLOGY VALUE FUND L P | 8,089,795 9.990% |
1,386,906 (+20.69%) |
Filing History |
| 2024-11-14 4:26 pm Sale |
2024-09-30 | 13G | Lexicon Pharmaceuticals, Inc. LXRX |
BIOTECHNOLOGY VALUE FUND L P | 0 0.000% |
-24,435,632 (Position Closed) |
Filing History |